Pulse Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
PLSE$55.12-5.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| Product revenues | $— | $700 |
| Total revenues | — | 700 |
| Cost and expenses: | ||
| Cost of revenues | — | 11,944 |
| Research and development | 27,797 | 20,839 |
| Sales and marketing | — | 12,019 |
| General and administrative | 15,777 | 13,955 |
| Total cost and expenses | 43,574 | 58,757 |
| Loss from operations | (43,574) | (58,057) |
| Other income (expense): | ||
| Interest income (expense), net | 1,364 | (448) |
| Total other income (expense) | 1,364 | (448) |
| Loss from operations, before income taxes | (42,210) | (58,505) |
| Income tax benefit | — | — |
| Net loss | (42,210) | (58,505) |
| Comprehensive loss | $(42,210) | $(58,505) |
| Net loss per share: | ||
| Basic and diluted net loss per share | $(0.88) | $(1.72) |
| Weighted average shares used to compute net loss per common share — basic and diluted | 48,038 | 33,935 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.